OpGen Inc - Company Profile
Powered by 
All the data and insights you need on OpGen Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date OpGen Inc Strategy Report
- Understand OpGen Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
OpGen Inc (OpGen) is a precision medicine company that harnesses molecular diagnostics and informatics to prevent infectious diseases caused by multi-drug resistant organisms (MDROs). OpGen develops products that include AREScloud, ARESd, Unyvero LRT Panels, Unyvero Urinary Tract Infection (UTI) Panel, Unyvero System, SARS-CoV-2 test kit, Acuitas molecular diagnostic and Acuitas Lighthouse informatics. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.
Headquarters
United States of America
Address
9717 Key West Avenue, Suite 100, Rockville, Maryland, 20850
Website
opgen.com
Telephone
1 301 8699683
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
OPGN (NASD)
Revenue (2021)
$2.6M
-39.5%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
-7.1%
(2021 vs 2020)
Market Cap*
$5.3M
Net Profit Margin (2021)
XYZ
-76.9%
(2021 vs 2020)
* As of and is in US$
OpGen Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Technology: | Surveillance Services |
| ARES Technology | Sequencing |
| NGS technology | ARESid |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In August, Curetis GmbH signed an extended and continued research and development agreement with FIND for the development of an AMR assay and Unyvero A30 cartridge for AMR detection. |
| 2023 | Contracts/Agreements | In April, the company entered into an agreement with Fisher Healthcare for distribution of OpGen’s Unyvero A50 platform and in vitro diagnostic (IVD) tests for bacterial pneumonia. |
| 2022 | Contracts/Agreements | In October, the company entered into an agreement with BioVersys for the deployment and use of the Unyvero platform in BioVersys’ upcoming Phase II clinical trial of novel drug candidate BV100. |
Competitor Comparison
| Key Parameters | OpGen Inc | Becton Dickinson and Co | Laboratory Corp of America Holdings | Quest Diagnostics Inc | bioMerieux SA |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | France |
| City | Rockville | Franklin Lakes | Burlington | Secaucus | Craponne |
| State/Province | Maryland | New Jersey | North Carolina | New Jersey | Rhone Alpes |
| No. of Employees | 100 | 73,000 | 67,000 | 40,000 | 14,651 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William E. Rhodes III | Chairman | Executive Board | 2020 | 69 |
| Oliver Schacht | Chief Executive Officer; Director | Executive Board | 2020 | 52 |
| Albert Weber | Chief Financial Officer; Secretary | Senior Management | 2022 | 60 |
| Johannes Bacher | Chief Operating Officer | Senior Management | 2020 | 54 |
| Faranak Atrzadeh | Chief Marketing Officer; Chief Scientific Affairs Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer